MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。动脉粥样硬化的多种族研究（梅萨）是一项为期10年的NHLBI资助的亚临床心血管疾病（在产生体征和症状之前非侵入性检测的疾病）多中心研究。本研究的总体目标是确定亚临床动脉粥样硬化患者的特征，以预测临床心脏病事件的进展。本研究的具体目的是：确定与临床心脏病相关的特征;确定亚临床疾病的新措施;并开发用于识别最高风险无症状者的方法，以用于未来的筛查和干预研究。我们将通过作为一个现场中心参与一项针对45-84岁基线时无临床心血管疾病证据的人群的协作、多中心、队列研究来实现这些目标。在研究的前18个月，我们目前正在参与合作方案的制定和试点研究阶段。我们将开始招募1,100名福赛斯县的成年人在WFUSM外地中心（包括50%的非洲裔美国人）开始在2000年夏天。将使用许多技术程序对参与者进行亚临床心血管疾病评估。这些数据对于更好地设计未来的临床和基于人群的干预计划，以进一步减轻美国心血管疾病的负担非常重要。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Multi-Ethnic Study of Atherosclerosis (MESA) is a 10-year NHLBI-funded multi-center study of subclinical cardiovascular disease (disease detected non-invasively before it has produced signs and symptoms). The overall goal of this study is to identify characteristics of persons with subclinical atherosclerosis that predict progression to clinical heart disease events. The specific aims of this study are: to determine characteristics related to clinical heart disease; to identify new measures of subclinical disease; and to develop methods for identifying the highest risk asymptomatic persons for application in future screening and intervention studies. We will accomplish these aims by participating as a field center in a collaborative, multi-center, cohort study of persons ages 45-84 years without evidence of clinical cardiovascular disease at baseline. We are currently participating in the collaborative protocol development and the pilot study phase, during the first 18 months of the study. We will begin recruiting 1,100 Forsyth County adults at the WFUSM field center (including 50% African Americans) beginning in the Summer of 2000. Participants will be evaluated for subclinical cardiovascular disease using a number of technologic procedures. These data will be important to better design future clinical and population-based intervention programs to further reduce the burden of cardiovascular disease in the United States.